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Abstract:  
 
OBJECTIVES The purpose of this study was to evaluate the impact of door-to-balloon time 
with primary percutaneous coronary intervention (PCI) on late cardiac mortality. 
 
BACKGROUND The impact of door-to-balloon time on outcomes is controversial, and the 
impact on late mortality has not been studied. 
 
METHODS Consecutive patients (n _ 2,322) treated with primary PCI from 1984 to 2003 were 
prospectively identified and followed up for a median of 83 months. 
 
RESULTS Prolonged door-to-balloon times (0 to 1.4 h vs. 1.5 to 1.9 h vs. 2.0 to 2.9 h vs. _3.0 
h) were associated with higher in-hospital mortality (4.9% vs. 6.1% vs. 8.0% vs. 12.2%, p _ 
0.0001) and late mortality (12.6% vs. 16.4% vs. 20.4% vs. 27.1% at 7 years, p _ 0.0001) and 
were an independent predictor of late mortality by Cox regression (p _ 0.0004). Prolonged door-
to-balloon times (_2 h vs. _2 h) were associated with higher late mortality in high-risk patients 
(32.5% vs. 21.5%; hazard ratio [HR], 1.53; 95% confidence interval [CI], 1.22 to 1.90; p _ 
0.0002) but not in low-risk patients (10.8% vs. 9.2%; HR, 1.13; 95% CI, 0.78 to 1.64; p _ 0.53) 
and in patients presenting early (_3 h) (24.7% vs. 15.0%; HR, 1.54; 95% 
CI, 1.24 to 1.90; p _ 0.0001) but not late (_3 h) (21.1% vs. 18.5%; HR, 0.95; 95% CI, 0.62 to 
1.45; p _ 0.80). 
 
CONCLUSIONS Delays in door-to-balloon time impact late survival in high-risk but not low 
risk patients and in patients presenting early but not late after the onset of symptoms. These 
findings have implications for the triage of patients for primary PCI. (J Am Coll Cardiol 
2006;47: 289–95) 
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Article:  
 
Primary percutaneous coronary intervention (PCI) has been shown to achieve superior outcomes 
compared with thrombolytic therapy in the treatment of ST-segment elevation acute myocardial 
infarction (STEMI) (1), and recent guide- lines have recommended primary PCI as the preferred 
reperfusion strategy when it can be performed by experienced operators in a timely fashion (2). 
However, primary PCI is often not immediately available, and frequently there are long 
treatment delays that could potentially impact outcomes. The impact of treatment delays with 
primary PCI on outcomes has been controversial. Some studies have shown that delays in door-
to-balloon time adversely affect outcomes (3,4),  whereas  other  studies  have  found  little 
correlation between door-to-balloon time and outcomes (5–7). None of these studies have 
evaluated the effect of door-to-balloon time on late cardiac mortality.  
 
We postulated that the differences in the relationship between door-to-balloon time and mortality 
may be related to differences in risk profile among studies. Consequently, we examined the 
relationship between door-to-balloon time and late cardiac mortality in our large database with 
primary PCI with special attention to subgroup analyses in high- and low-risk patients. 
 
METHODS 
 
Study population. Our study population was taken from 2,322 consecutive patients with STEMI 
treated with primary PCI without previous thrombolytic therapy at our institution from 1984 
through 2003. Patients with chest pain of <12 h duration or >12 h for persistent pain or 
hemodynamic compromise and with electrocardiographic ST-segment elevation >1 mm in >2 
contiguous leads or left bundle branch block and without severe co-morbid disease were selected 
for intervention. After excluding 22 patients with missing door-to-balloon time data, our analyses 
were performed on a study cohort of 2,300 patients. Treatment protocol.  Patients were treated 
with heparin and aspirin in the emergency department and transferred promptly to the 
catheterization laboratory for mechanical reperfusion. Stents were first used in 1995 and overall 
were used in 30% of patients. Platelet glycoprotein IIb/IIIa inhibitors were first used in 1996 and 
overall were used in 29% of patients. Ticlopidine or clopidogrel were used in stent patients and 
continued for at least one month. Beta- adrenergic blocking agents and nitrates were used at the 
operator’s discretion. 
 
 
 
Clinical and angiographic follow-up. Clinical follow-up was obtained by hospital and office 
chart review and telephone contact in 97% of hospital survivors at a median follow-up time of 83 
months. Follow-up catheterization and angiography were performed routinely during the first 
three years of the study and during participation in several clinical trials. Otherwise, follow-up 
catheterization was performed for recurrent ischemic symptoms or after abnormal functional test 
results. Follow-up catheterization procedures with angiography adequate for measurement of left 
ventricular ejection fraction were obtained in 40% of hospital survivors at a median follow-up 
time of 6.4 months. Definitions and data analysis.  Door-to-balloon time was the time from 
arrival at the presenting hospital until balloon inflation. Time to presentation was the time from 
symptom onset until arrival at the presenting hospital. Patients were classified as diabetic if they 
had been treated with insulin or oral hypoglycemic medication. Coronary flow in the infarct 
artery was assessed visually by the operator and classified according to the Thrombolysis In 
Myocardial Infarction (TIMI) grading system on a scale of 0 to 3 (8). Reinfarction was defined 
as recurrent chest pain associated with any secondary increase in the creatinine kinase level and 
the MB fraction higher than the nadir, with or without diagnostic electrocardiographic changes. 
Urgent target vessel revascularization was defined as the need for repeat PCI of the target vessel 
or bypass surgery for recurrent ischemia or hemodynamic compromise. High-risk patients were 
defined as patients with Killip class 3 to 4, age >70 years, or anterior infarction. Low-risk 
patients were all others. 
 
Left ventricular ejection fractions were calculated from tracing the contours of right anterior 
oblique cine angiograms using the area-length method with correction for the right anterior 
oblique projection (9). 
 
Statistical analysis. Statistical comparisons of categorical variables were performed using the 
chi-square test. Continuous variables are presented as mean values (±standard deviation), and 
statistical comparisons were performed using analysis of variance. Predictors of in-hospital 
mortality were evaluated with multiple logistical regression. Differences in late cardiac survival 
across categories of treatment times were examined with Kaplan-Meier survival curves and their 
associated Wilcoxon statistics. Predictors of late cardiac mortality were performed using Cox 
proportional hazards regression models. Variables entered into the models were age, gender, 
diabetes, prior infarction, prior bypass surgery, anterior infarction, Killip class, hypertension, 
smoking status, and door-to-balloon time. All analyses were performed with SAS (SAS Institute 
Inc., Cary, North Carolina) and SPSS (SPSS Inc., Chicago, Illinois) software. 
 
 
 
 
 
RESULTS 
 
Baseline variables by door-to-balloon time. The median (25th, 75th percentiles) door-to-
balloon  time was  2.3  h (1.6, 3.2) in all patients, 1.9 h (1.5, 2.5) in patients presenting at the 
interventional hospital, and 2.9 h (2.3, 3.9) in 871 patients transferred from non-interventional 
hospitals. Patients with longer door-to-balloon times were older, more often were women, and 
had a higher frequency of diabetes, anterior infarction, and Killip class 3 to 4, but had a lower 
frequency of previous infarction (Table 1). Acute ejection fraction was lower in patients with 
longer door-to-balloon times. A comparison of baseline variables in high- risk versus low-risk 
patients as previously defined is shown in Table 2. 
 
In-hospital outcomes by door-to-balloon time. In-hospital mortality was significantly higher 
with longer door-to-balloon times (Table 3). There were no significant correlations between 
door-to-balloon time and reinfarction or stroke. Peak values of creatinine kinase and the MB 
fraction were significantly higher in patients with longer door-to-balloon times (Table 3). 
 
After adjusting for differences in baseline variables, door- to-balloon time was a significant 
independent predictor of in-hospital mortality when expressed as a continuous variable (odds 
ratio [OR] = 1.06; 95% confidence interval [CI], 1.01 to 1.11; p=0.02) (OR expressed per 0.1 h) 
and as a categorical variable (compared with 0 to 1.4 h: 1.5 to 1.9 h, OR = 1.34, 95% CI, 0.67 to 
2.67; p = 0.41; 2.0 to 2.9 h: OR = 1.99; 95% CI, 1.07 to 3.69; p = 0.03; >3.0 h: OR = 2.38; 95% 
CI, 1.30 to 4.37; p = 0.005).  
 
Late cardiac mortality by door-to-balloon time. Prolonged door-to-balloon times (0 to 1.4 h 
vs. 1.5 to 1.9 h vs. 2.0 to 2.9 h vs. >3.0 h) were associated with higher late mortality (12.6% vs. 
16.4% vs. 20.4% vs. 27.1% at 7 years, p < 0.0001) with survival curves that diverged over time 
(Fig. 1). After adjusting for differences in baseline variables with Cox regression, door-to-
balloon time was a significant independent predictor of late cardiac mortality (Table 4). Door-to-
balloon time expressed as a continuous variable was also a significant independent predictor of 
late cardiac mortality (hazard ration [HR] = 1.04; 95% CI, 1.01 to 1.07; p = 0.003) (HR 
expressed per 0.1 h). 
 
Late cardiac mortality by door-to-balloon patient subgroups.  The effects of door-to-balloon 
times on late cardiac mortality in patient subgroups (with HRs adjusting for differences in 
baseline variables) are shown in Table 5. Delays in door-to-balloon time (>2 vs. <2 h) had a 
greater impact on late mortality in women versus men, anterior versus non-anterior infarction, 
Killip class 3 to 4 versus Killip  class  1  to  2,  early  (<3  h)  versus  late  (>3  h) presentation, 
and high- versus low-risk patients. High-risk patients were defined as patients with Killip class 3 
to 4, age >70 years, or anterior infarction. There were trends or significant interactions between 
door-to-balloon time and each of the following variables: gender (p = 0.06), infarct location (p = 
0.13), Killip class (p = 0.03), time to presentation (p = 0.16), and high- versus low-risk patients 
(p = 0.02). 
 
 
 
 
 
Kaplan-Meier unadjusted estimates of late cardiac survival show that prolonged door-to-balloon 
times (>2 vs. <2 h) were associated with higher late mortality in high-risk patients (32.5% vs. 
21.5% at seven years; HR, 1.53; 95% CI, 1.22 to 1.90; p = 0.0002) but not in low-risk patients 
(10.8% vs. 9.2%; HR, 1.13; 95% CI, 0.78 to 1.64; p = 0.53) (Table 5, Fig. 2). Survival curves 
also showed that prolonged door-to-balloon times (>2 vs. <2 h) were associated with higher late 
mortality in patients presenting early after the onset of symptoms (<3 h) (24.7% vs. 15.0% at 
seven years; HR, 1.54; 95% CI, 1.24 to 1.90; p = 0.0001) but not late after the onset of symptoms 
(>3 h) (21.1% vs. 18.5%; HR, 0.95; 95% CI, 0.62 to 1.45; p = 0.80) (Table 5, Fig. 3). 
 
DISCUSSION 
 
The major findings of this study are that delays in door-to- balloon time with primary PCI for 
STEMI have a major impact on late cardiac mortality, and this impact is seen primarily in high-
risk patients and patients who present early after the onset of symptoms. 
 
Previous studies.  Previous studies have shown conflicting results regarding the importance of 
door-to-balloon time on mortality (3–7).  Door-to-balloon  time  was  significantly correlated 
with in-hospital mortality in the Global Utilization of Streptokinase and Tissue Plasminogen 
Activator for Occluded Coronary Arteries (GUSTO)-IIb trial (3) and the National Registry of 
Myocardial Infarction (NRMI) (4). The NRMI Investigators found that door-to-balloon times >2 
h were associated with significantly increased mortality. 
 
Conversely, data from the Stent Primary Angioplasty in Myocardial Infarction (PAMI) trial (5), 
the Zwolle Group (6), and the Controlled Abciximab and Device Investigation to Lower Late 
Angioplasty Complications (CADILLAC) trial (7) found no significant correlation between 
door-to- balloon time and mortality (although the latter two trials did show a significant 
correlation between overall time to reperfusion and mortality). There may be several reasons for 
these differences. As documented in our study, delays in door-to-balloon time impact mortality 
primarily in high- risk patients. Study cohorts with large numbers of low-risk patients may not 
show a significant correlation between door-to-balloon time and mortality because of dilution of 
the study cohort with low-risk patients. Secondly, sicker patients may require additional 
procedures and additional evaluation (such as cardiopulmonary resuscitation, temporary 
pacemakers, intra-aortic balloon pumps, computed tomography scans, etc.), which create 
additional time delays before reperfusion. This potential bias for longer door-to- balloon times in 
sicker patients would be more pronounced in “real-world registries,” such as NRMI and our 
database, than in randomized trials. This is exemplified in our study, in which patients with the 
longest door-to-balloon times were older and had a much higher frequency of anterior infarction, 
diabetes, shock, and congestive heart failure. Thirdly, in large multicenter registries, door-to 
balloon time may be a surrogate for quality of care. Finally, studies that look at short-term 
mortality would not appreciate the effect of treatment delays on long-term mortality. 
 
Impact of treatment delays on mortality in subgroups. Our study found that delays in door-
to-balloon time had a major impact on late cardiac mortality in high-risk patients but had little 
effect in low-risk patients. Previous studies had not evaluated the relationship between door-to-
balloon time and mortality in high- and low-risk patients, but several studies had found that total 
time to reperfusion (time from symptom onset to balloon inflation) correlated with mortality in 
high-risk patients but not in low-risk patients (6,7,10,11). 
 
We found that delays in door-to-balloon time had a greater impact on late mortality in patients 
with Killip class 3 to 4 versus 1 to 2, in anterior versus non-anterior infarction, in women versus 
men, and in diabetic versus non-diabetic patients. We also found that delays in door- to-balloon 
time were associated with increased late mortality in patients presenting early (<3 h) but had 
little effect on mortality in patients presenting late after the onset of symptoms (>3 h). The 
CADILLAC investigators reported similar findings and found that delays in door-to-balloon time 
were associated with increased one-year mortality in patients presenting early (<2 h) but not in 
patients presenting late (>2 h) (7). 
 
 
 
Paradigm for the mechanism of benefit of reperfusion therapy. Our data suggesting that 
delays in door-to- balloon time impact mortality in patients presenting early but not late after the 
onset of symptoms are consistent with an expanded paradigm for the mechanism of mortality 
benefit with reperfusion therapy (12). In patients who undergo reperfusion therapy early, the 
mortality benefit may be related primarily to myocardial salvage, and this is very time 
dependent. In patients who undergo reperfusion later, the mortality benefit may be related to the 
effect of an open infarct artery in preventing left ventricular remodeling and in promoting 
electrical stability, and this is not very time dependent. Previous and recent studies have 
documented that to achieve significant myocardial salvage, reperfusion usually must be 
established at <2 to 3 h (13,14). 
 
 
 
Clinical implications. Our study has implications regarding the triage of patients with STEMI 
presenting at non-interventional hospitals. The results from recent randomized trials have found 
that outcomes are better when patients with STEMI who present at non-interventional hospitals 
are transferred to an interventional facility for primary PCI compared with being given 
fibrinolytic therapy at the local hospital (15–17). The additional treatment delays of primary PCI 
compared with fibrinolytic therapy in these trials ranged from 55 to 104 min. The optimum 
reperfusion strategy when delays to primary PCI are longer than this has not been evaluated.  
 
 
 
 
 
Our data indicate that in patients who present early after the onset of symptoms, delays in door-
to-balloon times with primary PCI seem to have a significant impact on late mortality. If these 
delays are long enough, primary PCI may lose its mortality advantage over fibrinolytic therapy. 
(The advantage of primary PCI over fibrinolytic therapy in reducing reinfarction with fewer 
complications of intracranial hemorrhage and stroke may be less time dependent.) The optimum 
reperfusion strategy in these patients may include alternative reperfusion strategies such as local 
fibrinolytic therapy or combined pharmacologic therapy and PCI (facilitated PCI). In contrast, in 
patients who present later, treatment delays have much less effect on mortality, and transfer for 
primary PCI may be the best reperfusion option, even with longer delays. The results of large 
ongoing randomized trials of facilitated PCI in patients with STEMI presenting to non-
interventional hospitals should help define the optimum reperfusion strategies in subgroups of 
patients who have long treatment delays to primary PCI. 
 
Door-to-balloon times in this study are quite long, especially for patients transferred from 
community hospitals to our institution. Similarly long door-to-balloon times have been recently 
reported from the NRMI (18). Although door-to-balloon times have improved some at our 
institution in recent years, the prolonged delays in this study and the NRMI emphasize the need 
in this country to develop better protocols for the triage and transfer of patients from community 
hospitals to interventional facilities. 
 
Study limitations. This is a single-center observational study, and there may be differences in 
baseline variables across categories of door-to-balloon times that may not be accounted for in the 
multivariable analyses and that may affect the relationship between door-to-balloon time and 
mortality. Our study spans two decades of experience. Although this allows for long-term 
follow-up, changes in adjunctive therapies with primary PCI could impact the relationship 
between door-to-balloon time and outcomes. However, we examined the relationship between 
door-to- balloon time and late mortality in the period before (1984 to 1995) and after (1996 to 
2003) the introduction of stents and glycoprotein IIb/IIIa platelet inhibitors and the relationships 
were similar. Finally, reperfusion may occur before balloon inflation, either spontaneously or as 
the result of the administration of heparin and aspirin, and in these patients the time to 
reperfusion is unknown. 
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